Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ALM.MC
- Price
- 12.30
- Stock movement down
- -0.60 (-4.65%)
- Company name
- Almirall S.A.
- Exchange
- (MC ,
- Currency
- EUR )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 2.64B
- Ent value
- 3.15B
- Price/Sales
- 2.45
- Price/Book
- 1.79
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- 108.42%
- Trailing P/E
- 62.77
- Forward P/E
- 23.46
- PEG
- -
- EPS growth
- -39.80%
- 1 year return
- 40.25%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2026-01-20
DIVIDENDS
ALM.MC does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 62.77 |
| Price to OCF | 11.67 |
| Price to FCF | 109.27 |
| Price to EBITDA | 17.06 |
| EV to EBITDA | 20.33 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.45 |
| Price to Book | 1.79 |
| EV to Sales | 2.92 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 214.58M |
| EPS (TTM) | 0.20 |
| FCF per share (TTM) | 0.11 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.08B |
| Gross profit (TTM) | 829.28M |
| Operating income (TTM) | 75.67M |
| Net income (TTM) | 42.05M |
| EPS (TTM) | 0.20 |
| EPS (1y forward) | 0.52 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 76.87% |
| Operating margin (TTM) | 7.01% |
| Profit margin (TTM) | 3.90% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 376.60M |
| Net receivables | 160.10M |
| Total current assets | 777.40M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 2.36B |
| Accounts payable | 0.00 |
| Short/Current long term debt | 337.10M |
| Total current liabilities | 305.40M |
| Total liabilities | 882.40M |
| Shareholder's equity | 1.48B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 226.08M |
| Capital expenditures (TTM) | 201.93M |
| Free cash flow (TTM) | 24.15M |
| Dividends paid (TTM) | 26.19M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 2.85% |
| Return on Assets | 1.78% |
| Return on Invested Capital | 2.32% |
| Cash Return on Invested Capital | 1.33% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 12.68 |
| Daily high | 12.72 |
| Daily low | 12.24 |
| Daily Volume | 261K |
| All-time high | 19.22 |
| 1y analyst estimate | 13.87 |
| Beta | 0.17 |
| EPS (TTM) | 0.20 |
| Dividend per share | 0.00 |
| Ex-div date | 15 May 2025 |
| Next earnings date | 23 Feb 2026 |
Downside potential
Loading...
Downside potential data
| ALM.MC | S&P500 | |
| Current price drop from All-time high | -36.00% | -2.53% |
| Highest price drop | -57.96% | -19.00% |
| Date of highest drop | 30 Dec 2024 | 8 Apr 2025 |
| Avg drop from high | -45.48% | -2.50% |
| Avg time to new high | - | 6 days |
| Max time to new high | 326 days | 89 days |
COMPANY DETAILS
Marketcap
2.64B
Marketcap category
Mid-cap
Description
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, nervous, and respiratory system; dermatologicals; genito urinary system and sex hormones; immunostimulants; metabolism; and systematic hormonal preparations. It has a multi-target partnership with Etherna to research and develop mRNA-based therapies for medical dermatology. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Employees
2026
Website
Investor relations
-
SEC filings
CEO
Country
Spain
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
BARCELONA, Spain, January 15, 2026--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, announces the planned start of a phase III study assessing the efficacy and ...
January 15, 2026
SAN FRANCISCO, January 14, 2026--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, is participating in the 44th J.P. Morgan Healthcare Conference 2026, taking pla...
January 14, 2026
Almirall (BME:ALM) shares edged higher today, gaining just under 2%. This move has caught the attention of investors, who are keen to understand what might be driving sentiment for the Spanish pharmac...
November 10, 2025
Almirall SA (FRA:E2Z) reports a robust 13% increase in net sales, driven by European dermatology, while navigating challenges in gross margin and SG&A expenses.
November 10, 2025
BARCELONA, Spain, November 10, 2025--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results for the first nine months of 2025. Almirall conti...
November 10, 2025
The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving this growth in...
October 23, 2025
NEWS RELEASE Milan, 23 October 2025 – Recordati, a global pharmaceutical company, announces today that Mike McClellan will join as its new Chief Financial Officer (CFO) as of January 1, 2026 and will ...
October 23, 2025
Almirall (BME:ALM) shares have quietly advanced this month, gaining 7% over the past four weeks. Investors might be paying closer attention to the company’s fundamentals as the company shows steady an...
October 13, 2025
If you are wondering whether now is the right moment to make a move on Almirall, you are definitely not alone. Over the last year, Almirall’s stock has turned quite a few heads, climbing a remarkable ...
October 13, 2025
In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Absci Corporation is one of them. Absci Corporation (NASDAQ:ABSI), founded in 2018 and headquartered in Se...
September 21, 2025
Next page